

DEPDC1B Antibody

Catalog # ASC11947

Product Information

Application	WB, E
Primary Accession	Q8WUY9
Other Accession	NP_060839 , 223633999
Reactivity	Human
Host	Rabbit
Clonality	Polyclonal
Isotype	IgG
Calculated MW	61771
Concentration (mg/ml)	1 mg/mL
Conjugate	Unconjugated
Application Notes	DEPDC1B antibody can be used for detection of DEPDC1B by Western blot at 1 - 2 μ g/ml.

Additional Information

Gene ID	55789
Other Names	DEP domain-containing protein 1B, HBV X-transactivated gene 8 protein, HBV XAg-transactivated protein 8, DEPDC1B, XTP8
Target/Specificity	DEPDC1B; DEPDC1B antibody is human specific. At least two isoforms are known to exist; this antibody will only detect the largest isoform. DEPDC1B antibody is predicted to not cross-react with DEPDC1A.
Reconstitution & Storage	DEPDC1B antibody can be stored at 4°C for three months and -20°C, stable for up to one year.
Precautions	DEPDC1B Antibody is for research use only and not for use in diagnostic or therapeutic procedures.

Protein Information

Name	DEPDC1B
Synonyms	XTP8

Background

The DEP domain-containing 1B (DEPDC1B) protein was initially identified as a radiation response biomarker in human lymphoblastoid cell lines (1). Like the related protein DEPDC1A, expression of DEPDC1B correlates with a poor prognosis in cancer patients (2,3). Studies have shown that DEPDC1B levels are upregulated in non-small cell lung cancer (NSCLC) and have an inverse correlation with patient survival. Ectopic expression

of DEPDC1B in NSCLC activated Wnt/B-catenin signaling and enhanced cell migration and invasion while silencing DEPDC1B expression suppressed these traits (2).


References

Niu N, Qin Y, Fridley BL, et al. Radiation pharmacogenomics: a genome-wide association approach to identify radiation response biomarkers using human lymphoblastoid cell lines. *Genome Res.* 2010; 20:1482-92.

Yang Y, Liu L, Cai J, et al. DEPDC1B enhances migration and invasion of non-small cell lung cancer cells via activating Wnt/B-catenin signaling. *Biochem. Biophys. Res. Commun.* 2014; 450:899-905.

Kassambara A, Schoenhals M, Moreaux J, et al. Inhibition of DEPDC1A, a bad prognostic marker in multiple myeloma, delays growth and induces mature plasma cell markers in malignant plasma cells. *PLoS One* 2013; 8:e62752.

Images



Western blot analysis of DEPDC1B in K562 cell lysate with DEPDC1B antibody at 1 µg/ml in (A) the absence and (B) the presence of blocking peptide.

Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.